[O6] Oral Presentations 6

8:30 〜 8:40R&D IIIClinical Research

[O6-01] 自己免疫疾患患者における複数回SARS-CoV-2 mRNAワクチン接種後の抗体応答の違い
Distinct antibody response trajectories after SARS-CoV-2 mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases: a group-based trajectory analysis

*Yasuhiro Kato^1,6,12, Yuta Yamaguchi^1,5,6,17,12, Saori Amiya^1,3,6,7,12, Shoichiro Inokuchi², Sayaka Nagao³, Kazuma Kosaka^1,6, Shinichiro Nameki^1,6,8, Teruaki Murakami^1,6,9, Yuko Yoshimine^1,6, Yasutaka Okita^1,6, Takahiro Kawasaki^1,6,10, Takayoshi Morita^1,11, Kohei Tsujimoto^1,6,12, Jun Fujimoto⁴, Masayuki Nishide^1,6, Sumiyuki Nishida^1,12,13, Masashi Narazaki^1,14, Atsushi Kumanogoh^{1,3,6,12,15,16} (1. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka (Japan), 2. Real World Evidence Division, Pharmaceutical Business Unit, JMDC Inc. (Japan), 3. Center for Infectious Diseases for Education and Research (CiDER), The University of Osaka (Japan), 4. Department of Clinical Immunology, Osaka International Medical & Science Center, (Japan), 5. Division of Pharmacology, Graduate School of Medicine, Kobe University (Japan), 6. Department of Immunopathology, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), The University of Osaka (Japan), 7. Department of Respiratory Medicine, Ikeda City Hospital (Japan), 8. Division of Rheumatology and Allergy, Osaka General Medical Center (Japan), 9. Department of Respiratory Medicine and Clinical Immunology, Nippon Life Hospital (Japan), 10. Division of Rheumatology and Clinical Immunology, University of Pittsburgh (USA), 11. The Center for Rheumatic Disease, Nara Medical University (Japan), 12. Center for Advanced Modalities and Drug Delivery Systems (CAMaD), The University of Osaka (Japan), 13. Strategic Global Partnership & X (Cross)-Innovation Initiative, Graduate School of Medicine, The University of Osaka and The University of Osaka Hospital (Japan), 14. Department of Advanced Clinical and Translational Immunology, Graduate School of Medicine, The University of Osaka (Japan), 15. Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), The University of Osaka (Japan), 16. Japan Agency for Medical Research and Development – Core Research for Evolutional Science and Technology (AMED–CREST), The University of Osaka (Japan), 17. Department of Pharmacology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (Japan))

閲覧にはパスワードが必要です

ログイン

または